Drugs in Dev. Cardiology/Vascular Diseases
Preclinical
Switzerland 
Lead Product(s) : HTX-001
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Innosuisse
Deal Size : $3.3 million
Deal Type : Funding
Details : The first project will advance lead HTX-001, an antisense oligonucleotide targeting lncRNA Wisper, a cardiac tissue-enriched driver of fibrosis in the heart and second project will aim to develop a next-generation oncology therapy targeting cancer-associ...
Product Name : HTX-001
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
March 05, 2022
Lead Product(s) : HTX-001
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Innosuisse
Deal Size : $3.3 million
Deal Type : Funding
Lead Product(s) : INS-3001
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Inositec’s INS-3001 Reduces Cardiovascular Calcification
Details : INS-3001 was found to be a potent and well tolerated inhibitor of pathological soft tissue calcification in preclinical studies.
Product Name : INS-3001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 02, 2020
Lead Product(s) : INS-3001
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
